ALBERT C. STRICKLER, M.D.; PAMELA C. KIBSEY, M.D.; HILLAR VELLEND, M.D.
To the editor: We compliment Dienstag and colleagues (1) on their timely study of the use of hepatitis B vaccine in hospital personnel. With a 97% seroconversion rate, one could reasonably omit postimmunization testing for surface antibody (anti-HBs) and be confident that most recipients have been protected.
The hepatitis B vaccine program at Toronto General Hospital (2) began in January 1983. To date we have completed the series of three injections of Heptavax-B (Merck Sharp & Dohme, West Point, Pennsylvania), 1.0 mL (20 µg) intramuscularly, according to the manufacturer's directions (November 1983), in more than 250 persons. They include employees
Learn more about subscription options.
Register Now for a free account.
STRICKLER AC, KIBSEY PC, VELLEND H. Seroconversion Rates with Hepatitis B Vaccine. Ann Intern Med. 1984;101:564. doi: 10.7326/0003-4819-101-4-564_1
Download citation file:
Published: Ann Intern Med. 1984;101(4):564.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only